Literature DB >> 8385705

Expression of Epstein-Barr virus nuclear antigen 1,2A and 2B in the baculovirus expression system: serological evaluation of human antibodies to these proteins.

A Hille1, K Klein, S Bäumler, F A Grässer, N Mueller-Lantzsch.   

Abstract

The Epstein-Barr virus encoded nuclear antigens 1,2A, and 2B (EBNA 1, EBNA 2A, and EBNA 2B) were expressed in a baculovirus system. The full length recombinant proteins were recognized by polyclonal rabbit sera and by human sera. An immunofluorescence (IF) test for the differentiation between EBNA 1 and EBNA 2 antibodies in human sera was established with the expressed proteins. None of 55 sera of patients with infectious mononucleosis (IM) had anti-EBNA 1 antibodies while 36 of these sera had anti-EBNA 2A antibodies. Conversely, 47 of 51 sera from EBV-positive healthy carriers had anti-EBNA 1 antibodies and 18 of these sera had anti-EBNA 2A antibodies. The sensitivity and specificity of the EBNA 1 IF for the diagnosis of IM were higher as compared to conventional anti-complement immunofluorescence (ACIF). In the IF test differentiation between type A and type B EBV infection was only possible in sera from the IM patients. An immunoblot (IB) with low amounts of baculovirus expressed EBNA 2A and EBNA 2B antigen was carried out. Twenty-nine of 31 sera from IM patients or from healthy carriers with EBNA 2 antibodies reacted predominantly with EBNA 2A, whereas a known type B serum reacted strongly with EBNA 2B than with EBNA 2A.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385705     DOI: 10.1002/jmv.1890390311

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

Review 1.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Authors:  Wei Bu; Gregory M Hayes; Hui Liu; Lorraine Gemmell; David O Schmeling; Pierce Radecki; Fiona Aguilar; Peter D Burbelo; Jennifer Woo; Henry H Balfour; Jeffrey I Cohen
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

3.  Anti-EBNA1/anti-EBNA2 ratio decreases significantly in patients with progression of HIV infection.

Authors:  B Winkelspecht; F Grässer; H W Pees; N Mueller-Lantzsch
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

4.  Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method.

Authors:  Barbara C Gärtner; Ralf D Hess; Dirk Bandt; Alexander Kruse; Axel Rethwilm; Klaus Roemer; Nikolaus Mueller-Lantzsch
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

5.  CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.

Authors:  H M Long; T A Haigh; N H Gudgeon; A M Leen; C-W Tsang; J Brooks; E Landais; E Houssaint; S P Lee; A B Rickinson; G S Taylor
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.

Authors:  Heather M Long; Odette L Chagoury; Alison M Leese; Gordon B Ryan; Eddie James; Laura T Morton; Rachel J M Abbott; Shereen Sabbah; William Kwok; Alan B Rickinson
Journal:  J Exp Med       Date:  2013-04-08       Impact factor: 14.307

Review 7.  The T-cell Response to Epstein-Barr Virus-New Tricks From an Old Dog.

Authors:  Heather M Long; Benjamin J Meckiff; Graham S Taylor
Journal:  Front Immunol       Date:  2019-09-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.